Cancer Clinical Trial -Dracen Pharmaceuticals-DRA-104-001
Cancer
Status:
OpenClinicalTrials.gov:
NCT04471415First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.